Predictors of nonadherence to oral adjuvant hormonal therapy for breast cancer. Background: New targeted therapies have improved the prognosis of patients with breast cancer but cause several ...
Longer-term cardiac safety and outcomes of dose dense (dd) doxorubicin and cyclophosphamide (AC) followed by paclitaxel (T) and trastuzumab (H) with and without lapatinib (L) in patients (pts) with ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results